Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction

Author(s): Antonio Aversa, Massimiliano Caprio, Giuseppe M.C. Rosano, Giovanni Spera

Journal Name: Current Pharmaceutical Design

Volume 14 , Issue 35 , 2008

Become EABM
Become Reviewer
Call for Editor


Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage. The pathogenesis of endothelial dysfunction and ED is intimately linked through decreased expression and activation of endothelial nitric oxide (NO) synthase and the subsequent physiologic actions of NO. Furthermore, reduced biologic activity of endotheliumderived NO links atherosclerosis to ED and underscores the role of altered endothelium in the pathogenesis of both conditions. Evidence-based data suggest that daily use of phosphodiesterase type-5 inhibitors (PDE5-i) improves endothelial and erectile functions and that this benefit is lost upon drug withdrawal. Daily PDE5-i may also improve lower tract urinary symptoms related to benign prostatic hyperplasia through a reduction of adrenergic overtone. The relevance for these drugs in the prevention of complications in internal medicine diseases, i.e. cardiovascular disease, clotting disorders and autoimmune disease is uncertain. Finally, endothelial dysfunction is present in testosterone deficiency syndromes and replacement therapy is able to revert ED and to improve endothelial function. Aim of the present review is to discuss the systemic effects of drugs designed to treat ED, such as testosterone and PDE5- i, with regard to safety, unwanted effects and efficacy in improving endothelial function; finally, a goal-oriented approach to rehabilitation using daily vs. on-demand PDE5-i in difficult patients is discussed.

Keywords: Endothelial dysfunction, nitric oxide, testosterone, phosphodiesterase type-5 inhibitors, benign prostatic hyperplasia, LUTS, rehabilitation, internal medicine

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [3768 - 3778]
Pages: 11
DOI: 10.2174/138161208786898725
Price: $65

Article Metrics

PDF: 11